Olanzapine/fluoxetine combination for treatment-resistant depression: efficacy and clinical utility

References

• Trivedi MH, Rush AJ, Wisniewski SR et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am. J. Psychiatry163(1), 28–40 (2006).
   PubMed Web of Science ®Google Scholar
• Burrows GD, Norman TR, Judd FK. Definition and differential diagnosis of treatment-resistant depression. Int. Clin. Psychopharmacol.9(Suppl. 2), 5–10 (1994).
   PubMedGoogle Scholar
• Thase ME. What role do atypical antipsychotic drugs have in treatment-resistant depression? J. Clin. Psychiatry63(2), 95–103 (2002).
   PubMed Web of Science ®Google Scholar
• Souery D, Papakostas GI, Trivedi MH. Treatment-resistant depression. J. Clin. Psychiatry67(Suppl. 6), 16–22 (2006).
   PubMed Web of Science ®Google Scholar
• Dodd S, Horgan D, Malhi GS, Berk M. To combine or not to combine? A literature review of antidepressant combination therapy. J. Affect. Disord.89(1–3), 1–11 (2005).
   PubMed Web of Science ®Google Scholar
• Nemeroff CB. Augmentation strategies in patients with refractory depression. Depress. Anxiety4(4), 169–181 (1996).
   PubMedGoogle Scholar
• Brent D, Emslie G, Clarke G et al. Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial. JAMA299(8), 901–913 (2008).
   PubMed Web of Science ®Google Scholar
• Brent DA, Holder D, Kolko D et al. A clinical psychotherapy trial for adolescent depression comparing cognitive, family, and supportive therapy. Arch. Gen. Psychiatry54(9), 877–885 (1997).
   PubMed Web of Science ®Google Scholar
• Lau MA. New developments in psychosocial interventions for adults with unipolar depression. Curr. Opin. Psychiatry21(1), 30–36 (2008).
   PubMed Web of Science ®Google Scholar
• Martinez J, Garakani A, Marcus S et al. A randomized, double-blind, placebo controlled trial of quetiapine combined with fluoxetine in major depressive disorder. Presented at: 59th Institute of Psychiatric Services Conference. LA, USA, 11–14 October 2007.
   Google Scholar
• McIntyre A, Gendron A. Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study. Depress. Anxiety24(7), 487–494 (2007).
   PubMed Web of Science ®Google Scholar
• Berman RM, Marcus RN, Swanink R et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J. Clin. Psychiatry68(6), 843–853 (2007).
   PubMed Web of Science ®Google Scholar
• El-Khalili N, Joyce M, Atkinson S et al. Adjunctive extended-release quetiapine fumarate (quetiapine XR) in patients with major depressive disorder and inadequate antidepressant response. Presented at:American Psychiatric Association Annual Meeting. DC, USA, 3–8 May 2008.
   Google Scholar
• Beasley CM Jr, Tollefson G, Tran P et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology14(2), 111–123 (1996).
   PubMed Web of Science ®Google Scholar
• Shelton RC, Tollefson GD, Tohen M et al. A novel augmentation strategy for treating resistant major depression. Am. J. Psychiatry158(1), 131–134 (2001).
   PubMed Web of Science ®Google Scholar
• Beasley CM Jr, Dornseif BE, Bosomworth JC et al. Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression. BMJ303(6804), 685–692 (1991).
   PubMed Web of Science ®Google Scholar
• Weisler R, Joyce M, McGill L et al. Extended release quetiapine fumarate (quetiapine XR) monotherapy for major depressive disorder (MDD): a double-blind, placebo-controlled study. Presented at: American Psychiatric Association Annual Meeting. DC, USA, 3–8 May 2008.
   Google Scholar
• Datto C, Lam RW, Lepola U et al. Double-blind study of extended release quetiapine fumarate (quetiapine XR) monotherapy for maintenance treatment of major depressive disorder (MDD). Presented at: American Psychiatric Association Annual Meeting. DC, USA, 3–8 May 2008.
   Google Scholar
• Lecrubier Y, Boyer P, Turjanski S, Rein W. Amisulpride versus imipramine and placebo in dysthymia and major depression. Amisulpride Study Group. J. Affect. Disord.43(2), 95–103 (1997).
   PubMed Web of Science ®Google Scholar
• Dunner DL, Amsterdam JD, Shelton RC, Loebel A, Romano SJ. Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: a randomized, open-label, pilot study. J. Clin. Psychiatry68(7), 1071–1077 (2007).
   PubMed Web of Science ®Google Scholar
• Gharabawi G, Canuso C, Pandina G et al. A double-blind placebo-controlled study of adjunctive risperidone for treatment-resistant major depressive disorder. Int. J. Neuropsychopharmacology9(Suppl. 1), S236 (2006).
   Google Scholar
• Ostroff RB, Nelson JC. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J. Clin. Psychiatry60(4), 256–259 (1999).
   PubMed Web of Science ®Google Scholar
• Gossen D, de Suray JM, Vandenhende F, Onkelinx C, Gangji D. Influence of fluoxetine on olanzapine pharmacokinetics. AAPS PharmSci.4(2), E11 (2002).
   PubMed Web of Science ®Google Scholar
• Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM. Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin. Pharmacokinet.37(3), 177–193 (1999).
   PubMed Web of Science ®Google Scholar
• Hiemke C, Hartter S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol. Ther.85(1), 11–28 (2000).
   PubMed Web of Science ®Google Scholar
• Mandrioli R, Forti GC, Raggi MA. Fluoxetine metabolism and pharmacological interactions: the role of cytochrome p450. Curr. Drug Metab.7(2), 127–133 (2006).
   PubMed Web of Science ®Google Scholar
• Bymaster FP, Calligaro DO, Falcone JF et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology14(2), 87–96 (1996).
   PubMed Web of Science ®Google Scholar
• Bymaster FP, Hemrick-Luecke SK, Perry KW, Fuller RW. Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, α1-adrenergic and muscarinic receptors in vivo in rats. Psychopharmacology (Berl.)124(1–2), 87–94 (1996).
   PubMed Web of Science ®Google Scholar
• Owens MJ, Knight DL, Nemeroff CB. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol. Psychiatry50(5), 345–350 (2001).
   PubMed Web of Science ®Google Scholar
• DeVane CL. Differential pharmacology of newer antidepressants. J. Clin. Psychiatry59(Suppl. 20), 85–93 (1998).
   PubMed Web of Science ®Google Scholar
• Zhang W, Perry KW, Wong DT et al. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology23(3), 250–262 (2000).
   PubMed Web of Science ®Google Scholar
• Huang M, Ichiwaka J, Li Z, Dai J, Meltzer HY. Augmentation by citalopram of risperidone-induced monoamine release in rat prefrontal cortex. Psychopharmacology (Berl.)185(3), 274–281 (2006).
   PubMed Web of Science ®Google Scholar
• Moller HJ. Antipsychotic and antidepressive effects of second generation antipsychotics: two different pharmacological mechanisms? Eur. Arch. Psychiatry Clin. Neurosci.255(3), 190–201 (2005).
   PubMed Web of Science ®Google Scholar
• Jensen NH, Rodriguiz RM, Caron MG et al.N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1α agonist, as a putative mediator of quetiapine’s antidepressant activity. Neuropsychopharmacology33(10), 2303–2312 (2008).
   PubMed Web of Science ®Google Scholar
• Rothschild AJ, Williamson DJ, Tohen MF et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. J. Clin. Psychopharmacol.24(4), 365–373 (2004).
   PubMed Web of Science ®Google Scholar
• Brown EB, McElroy SL, Keck PE Jr et al. A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J. Clin. Psychiatry67(7), 1025–1033 (2006).
   PubMed Web of Science ®Google Scholar
• Tohen M, Vieta E, Calabrese J et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch. Gen. Psychiatry60(11), 1079–1088 (2003).
   PubMed Web of Science ®Google Scholar
• Corya SA, Perlis RH, Keck PE Jr et al. A 24-week open-label extension study of olanzapine-fluoxetine combination and olanzapine monotherapy in the treatment of bipolar depression. J. Clin. Psychiatry67(5), 798–806 (2006).
   PubMed Web of Science ®Google Scholar
• Dube S, Tollefson GD, Thase ME et al. Onset of antidepressant effect of olanzapine and olanzapine/fluoxetine combination in bipolar depression. Bipolar Disord.9(6), 618–627 (2007).
   PubMed Web of Science ®Google Scholar
• Shi L, Namjoshi MA, Swindle R et al. Effects of olanzapine alone and olanzapine/fluoxetine combination on health-related quality of life in patients with bipolar depression: secondary analyses of a double-blind, placebo-controlled, randomized clinical trial. Clin. Ther.26(1), 125–134 (2004).
   PubMedGoogle Scholar
• Keck PE Jr, Corya SA, Altshuler LL et al. Analyses of treatment-emergent mania with olanzapine/fluoxetine combination in the treatment of bipolar depression. J. Clin. Psychiatry66(5), 611–616 (2005).
   PubMed Web of Science ®Google Scholar
• Zanarini MC, Frankenburg FR, Parachini EA. A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. J. Clin. Psychiatry65(7), 903–907 (2004).
   PubMed Web of Science ®Google Scholar
• Dube S, Andersen SW, Paul S et al. Metanalysis of olanzapine/fluoxetine use in treatment-resistant depression. Presented at: XXIII CINP Congress – Collegium Internationale Neuro-Psychopharmacologicum (CINP). QC, Canada, 23–27 June 2002.
   Google Scholar
• Shelton RC, Williamson DJ, Corya SA et al. Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. J. Clin. Psychiatry66(10), 1289–1297 (2005).
   PubMed Web of Science ®Google Scholar
• Corya SA, Williamson D, Sanger TM et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depress. Anxiety23(6), 364–372 (2006).
   PubMed Web of Science ®Google Scholar
• Thase ME, Corya SA, Osuntokun O et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. J. Clin. Psychiatry68(2), 224–236 (2007).
   PubMed Web of Science ®Google Scholar
• Corya SA, Andersen SW, Detke HC et al. Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination: a 76-week open-label study. J. Clin. Psychiatry64(11), 1349–1356 (2003).
   PubMed Web of Science ®Google Scholar
• Girgis RR, Duggal HS, Douaihy AB. Respiratory depression from Symbyax overdose and binge drinking. Gen. Hosp. Psychiatry28(3), 255–256 (2006).
   PubMedGoogle Scholar
• Berk M, Dodd S, Callaly P et al. History of illness prior to a diagnosis of bipolar disorder or schizoaffective disorder. J. Affect. Disord.103(1–3), 181–186 (2007).
   PubMed Web of Science ®Google Scholar
• Goethe JW, Woolley SB, Cardoni AA, Woznicki BA, Piez DA. Selective serotonin reuptake inhibitor discontinuation: side effects and other factors that influence medication adherence. J. Clin. Psychopharmacol.27(5), 451–458 (2007).
   PubMed Web of Science ®Google Scholar
• Bull SA, Hu XH, Hunkeler EM et al. Discontinuation of use and switching of antidepressants: influence of patient-physician communication. JAMA288(11), 1403–1409 (2002).
   PubMed Web of Science ®Google Scholar
• Moore D. Dan Moore, President and CEO, Cyberonics, Inc. Presented at: Lazard Capital Markets, Fourth Annual Healthcare Conference. NY, USA, 27 November 2007.
   Google Scholar
• Crown WH, Finkelstein S, Berndt ER et al. The impact of treatment-resistant depression on health care utilization and costs. J. Clin. Psychiatry63(11), 963–971 (2002).
   PubMed Web of Science ®Google Scholar
• Kapczinski F, Vieta E, Andreazza AC et al. Allostatic load in bipolar disorder: implications for pathophysiology and treatment. Neurosci. Biobehav. Rev.32(4), 675–692 (2008).
   PubMed Web of Science ®Google Scholar
• Sheline YI, Sanghavi M, Mintun MA, Gado MH. Depression duration but not age predicts hippocampal volume loss in medically healthy women with recurrent major depression. J. Neurosci.19(12), 5034–5043 (1999).
   PubMed Web of Science ®Google Scholar
• Ng F, Berk M, Dean O, Bush AI. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int. J. Neuropsychopharmacol.21, 1–26 (2008).
   Google Scholar
• Berk M, Ng F, Dean O, Dodd S, Bush AI. Glutathione: a novel treatment target in psychiatry. Trends Pharmacol. Sci.29, 346–351 (2008).
   PubMed Web of Science ®Google Scholar
• Pasco JA, Jacka FN, Williams LJ et al. Leptin in depressed women: cross-sectional and longitudinal data from an epidemiologic study. J. Affect. Disord.107(1–3), 221–225 (2008).
   PubMed Web of Science ®Google Scholar
• Berk M, Dodd S, Kauer-Sant’anna M et al. Dopamine dysregulation syndrome: implications for a dopamine hypothesis of bipolar disorder. Acta Psychiatr. Scand. Suppl. (434), 41–49 (2007).
   PubMedGoogle Scholar
• Shelton CI. Long-term management of major depressive disorder: are differences among antidepressant treatments meaningful? J, Clin. Psychiatry65(Suppl. 17), 29–33 (2004).
   PubMedGoogle Scholar